Systemic Sclerosis Pipeline Analysis Report 2026

Systemic sclerosis (SSc) is a rare autoimmune connective‑tissue disorder marked by fibrosis of the skin and internal organs, leading to significant morbidity. As per Elena Schiopu et al., 2026, the global prevalence is estimated at about 17.6-18.9 per 100,000 individuals, with incidence ranging from 1.4-8.6 per 100,000 person‑years. Current and emerging therapies focus on immunomodulation, anti‑fibrotic agents, and organ‑specific management. Driven by unmet clinical needs, advances in targeted treatments and precision medicine are fueling robust pipeline growth. According to a systemic sclerosis pipeline analysis, factors such as rising autoimmune disease awareness, improved diagnostics, and demographic shifts are expected to propel market expansion in the coming years.

Report Coverage

The Systemic Sclerosis Pipeline Analysis Report gives comprehensive insights into systemic sclerosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for systemic sclerosis. The systemic sclerosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The systemic sclerosis pipeline landscape will include an analysis based on efficacy and safety measures outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with systemic sclerosis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to systemic sclerosis.

Systemic Sclerosis Pipeline Outlook

Systemic sclerosis, also known as scleroderma, is a rare, progressive autoimmune disease characterised by excessive inflammation and fibrosis. It leads to skin hardening and may affect internal organs, including lungs, heart, and kidneys, with interstitial lung disease. The exact cause involves immune system dysregulation and abnormal collagen deposition.

Systemic sclerosis treatments focus on managing complications and slowing progression. Current therapies include immunosuppressants, tyrosine kinase inhibitors, biologics, and supportive care targeting organ-specific manifestations, as no therapy currently reverses the underlying fibrosis. AnaMar’s AM1476, reported in February 2024, is advancing in the systemic sclerosis market drug pipeline. As an oral 5-HT2B receptor antagonist, it is designed to halt fibrosis-related signalling pathways in skin and lung tissue. A Phase II clinical trial enrolling approximately 60 patients will assess lung function and skin thickness over a year, aiming to provide a dual-action therapeutic approach.

Systemic Sclerosis Epidemiology

The pipeline is expanding amid rising epidemiological trends. According to Elena Schiopu et al., 2026, the global incidence of SSc ranges from 1.4 to 8.6 per 100,000 person-years, with higher rates in the United States (15.1-18.3) and lower rates in South Korea and the Netherlands (0.8). Prevalence is increasing worldwide, reported between 17.6 and 18.9 per 100,000 individuals, with Italy at 56.8 and the United States between 13.5-72.1 per 100,000. SSc predominantly affects females, with pooled incidence of 2.3-14.2 per 100,000 person-years versus 0.5-3.2 in males. Trends indicate sustained global demand for effective therapies.

Systemic Sclerosis - Pipeline Therapeutic Assessment

This section of the report covers the analysis of systemic sclerosis drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The systemic sclerosis pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Gene Therapies
• Peptides
• Polymers

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Systemic Sclerosis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I, with 40%, covers a major share of the total systemic sclerosis clinical trials, reflecting robust early-stage development that can expand treatment options. Phase II holds 35%, driving efficacy evaluation and potential market readiness. Early phase I contributed 12%, fostering innovation and novel therapies. Phase III accounts for 9%, supporting late-stage validation, while phase IV at 5% ensures post-marketing insights, collectively enhancing market growth.

Systemic Sclerosis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the systemic sclerosis pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The systemic sclerosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for systemic sclerosis. Immune cell-based therapies are gaining attention in the systemic sclerosis market to address unmet patient needs. For example, ADI-001, an allogeneic gamma delta chimeric antigen receptor T cell therapy targeting CD20, is under investigation by Adicet Bio. It aims to deplete B-cells in blood and secondary lymphoid tissue, potentially reducing disease activity and improving outcomes in patients with systemic sclerosis.

Systemic Sclerosis Clinical Trials - Key Players

The report for the systemic sclerosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed systemic sclerosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in systemic sclerosis clinical trials:

• Cabaletta Bio
• Kyverna Therapeutics
• Juno Therapeutics, Inc. (a Bristol-Myers Squibb Company)
• Jiangsu Renocell Biotech Company
• Mediar Therapeutics
• PersonGen BioTherapeutics (Suzhou) Co., Ltd.
• Tanabe Pharma Corporation
• AstraZeneca
• Argenx
• Novartis Pharmaceuticals
• Zura Bio Inc.
• GlaxoSmithKline

Systemic Sclerosis - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for systemic sclerosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of systemic sclerosis drug candidates.

Drug: BMS-986353

BMS-986353 (Zolacaptagene-autoleucel / Zola-cel) is a CD19-targeted NEX-T CAR T cell therapy being developed by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, for active systemic sclerosis. Administered as a single intravenous infusion following lymphodepletion, the therapy uses patients’ own T cells, collected via apheresis and engineered through a next-generation five-day NEX-T process, to target pathogenic CD19-expressing cells driving disease activity. This Phase 3, multicenter, open-label study is comparing BMS-986353 against standard of care, assessing safety for up to two years and efficacy at 24 weeks, with an estimated completion in November 2030.

Biological: CABA-201

CABA-201 is a CD19-specific chimeric antigen receptor (CAR) T cell therapy being developed by Cabaletta Bio for systemic sclerosis (SSc). This Phase 1/2 open-label study examines the safety and efficacy of a single intravenous infusion of CABA-201 in combination with cyclophosphamide and fludarabine. The therapy works by transiently depleting CD19-positive B cells, potentially “resetting” the immune system and enabling durable remission in autoimmune conditions. The study is actively recruiting 12 participants and is expected to complete in July 2029. Cabaletta Bio is leading the trial under FDA IND clearance for multiple autoimmune disorders.

Biological: KYV-101

KYV-101 is an autologous, fully human anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, designed to selectively target and deplete B-cells involved in systemic sclerosis (SSc). Administered intravenously following a standard lymphodepletion regimen, KYV-101 harnesses cytotoxic T-cells to lyse pathogenic B-cells in circulation and tissues, potentially reducing autoantibody-mediated fibrosis and vasculopathy. Sponsored by Kyverna Therapeutics, this Phase 1/2, open-label, multicenter study is examining the safety, tolerability, and preliminary efficacy of KYV-101 in adults with SSc. The trial started in August 2024, with primary completion expected by March 2026 and study completion by March 2027.

Key Questions Answered in the Systemic Sclerosis Pipeline Insight Report

• Which companies/institutions are leading the systemic sclerosis drug development?
• Which company is leading the systemic sclerosis pipeline development activities?
• What is the current systemic sclerosis commercial assessment?
• What are the opportunities and challenges present in the systemic sclerosis pipeline landscape?
• What is the efficacy and safety profile of systemic sclerosis pipeline drugs?
• Which company is conducting major trials for systemic sclerosis drugs?
• Which companies/institutions are involved in systemic sclerosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in systemic sclerosis?

Reasons To Buy This Report

The Systemic Sclerosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for systemic sclerosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into systemic sclerosis collaborations, regulatory environments, and potential growth opportunities.